Guillain-Barré syndrome

Guillain-Barré syndrome (GBS) is an acute immune-mediated disorder of the peripheral nerves and nerve roots. Weakness and sensory symptoms usually develop over days and can progress quickly. Cranial-nerve, breathing, swallowing, autonomic, and pain symptoms may also occur. GBS can affect any age and is more common in adults and males.1

Urgent safety

Suspected GBS requires urgent hospital assessment and monitoring. Seek emergency care for new or worsening weakness, difficulty walking, facial weakness, trouble speaking or swallowing, shortness of breath, inability to clear secretions, fainting, or marked heart-rate or blood-pressure symptoms. Respiratory and autonomic deterioration can occur even when limb weakness initially seems limited.1

GBS often follows a respiratory or gastrointestinal infection; Campylobacter jejuni is a common trigger. Most cases are not associated with vaccination, and the exact trigger is not always identified.1

Clinical pattern and diagnosis

The classic pattern is progressive, relatively symmetric weakness with reduced or absent reflexes. Tingling, numbness, pain, facial or eye-movement weakness, ataxia, and autonomic instability can occur. Recognized variants include acute inflammatory demyelinating polyneuropathy, acute motor axonal neuropathy, and Miller Fisher syndrome.2

Diagnosis is clinical and excludes urgent alternatives. Cerebrospinal-fluid analysis and nerve-conduction or other electrodiagnostic studies support the diagnosis, but results can be nondiagnostic early and no single test replaces serial examination. A course that continues to progress beyond the expected acute interval or repeatedly fluctuates may prompt reconsideration of another diagnosis such as acute-onset CIDP.2

Typical GBS affects peripheral motor, sensory, and autonomic nerves; it does not inherently cause intellectual disability, developmental language disorder, hyperactivity, or loss of literacy. Critical illness, medication effects, sleep loss, or other complications can still affect attention and participation.

Acute treatment and recovery

Treatment is delivered in a monitored medical setting. Intravenous immunoglobulin and plasma exchange are the established immune treatments for people who meet treatment criteria; routine corticosteroids are not recommended for GBS. Respiratory support, prevention and treatment of complications, pain care, and early rehabilitation are also important.1

Recovery varies. Many people recover well, but improvement can take months or longer and some have persistent weakness, sensory change, pain, or fatigue. Rehabilitation should respond to current endurance and function rather than promise full recovery or assume lifelong dependence.1

Swallowing and communication

Facial, bulbar, and respiratory weakness can reduce speech volume or clarity and make chewing, swallowing, coughing, and secretion management unsafe. New swallowing or voice change during acute GBS should be reported immediately to the hospital team; diet texture and swallowing strategies require direct clinical assessment.

Language and literacy are usually available for communication even when speech and movement are severely limited. Establish a reliable method early and reassess it as weakness changes:

• confirm an unambiguous yes/no response and an emergency call signal;
• use writing, alphabet or word boards, text-to-speech, or speech-generating AAC when appropriate;
• trial direct touch, mouse or pointer access, switches, partner-assisted scanning, or eye gaze from actual motor and visual performance;
• minimize effort, optimize positioning, and provide frequent rest;
• keep a low-tech backup available during procedures, transfers, power loss, or fatigue.

Do not assume symbol-based language, cognitive impairment, or a permanent device need. AAC may be temporary, may change rapidly, and should preserve the person's existing language and decision-making role.4 For the general evaluation, trial, funding, and implementation process, use the AAC device acquisition guide.

Coding

• ICD-10-CM G61.0: Guillain-Barré syndrome.
• ICD-10-CM G65.0: Sequelae of Guillain-Barré syndrome.

Use the code that matches active disease versus documented residual effects under the current local coding rules.5

Sources

1. World Health Organization: Guillain-Barré syndrome — current clinical overview, urgent monitoring, treatment, and variable recovery (updated October 24, 2025).
2. van Doorn et al. EAN/PNS Guideline on diagnosis and treatment of Guillain-Barré syndrome — evidence-based diagnosis, monitoring, treatment, and prognosis guidance (2023; PMID 37814551).
3. Centers for Disease Control and Prevention: GBS and flu vaccine — infection and vaccine-risk context.
4. American Speech-Language-Hearing Association: Augmentative and Alternative Communication — individualized, multimodal AAC assessment.
5. ICD-10-CM G61.0 / G65.0 — Guillain-Barré syndrome and sequelae descriptors; confirm against current CMS ICD-10-CM files.

Review boundary

This guide cannot diagnose or triage suspected GBS remotely. Rapid weakness, swallowing difficulty, breathing change, or autonomic symptoms require emergency assessment. Rehabilitation, swallowing, and communication recommendations require direct assessment and coordination with the treating neurologic and critical-care teams.